Elad Mark - 01 Jan 2023 Form 3 Insider Report for BiondVax Pharmaceuticals Ltd. (BVXV)

Role
Chief Operating Officer
Signature
/s/ Elad Mark
Issuer symbol
BVXV
Transactions as of
01 Jan 2023
Transactions value $
$0
Form type
3
Filing time
03 Jan 2023, 14:02:09 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BVXV Restricted Share Units 01 Jan 2023 Ordinary Shares 360,000 Direct F1, F2
holding BVXV Restricted Share Units 01 Jan 2023 Ordinary Shares 1,412,000 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents four hundred Ordinary Shares.
F2 Each restricted share unit represents a contingent right to receive one ordinary share.